Clinical Trials | October 22, 2025
AbbVie's Rinvoq beats Humira in key arthritis trial
The SELECT-SWITCH study, first head-to-head Phase 3b/4 trial, compared switching to Rinvoq versus switching to another TNF inhibitor
The SELECT-SWITCH study, first head-to-head Phase 3b/4 trial, compared switching to Rinvoq versus switching to another TNF inhibitor
This partnership marks a significant step in strengthening Healthium’s position in the cardiac care segment
IND clearance enables initiation of Phase 1c clinical trial in HFpEF patients with elevated endotrophin levels
The company plans to use the funds raised from the net proceeds to repay or prepay certain loans
FineCross M3 empowers physicians to perform safer PCI procedures, helping improve outcomes in patients with challenging coronary anatomies
The new algorithm will be introduced as part of Roche’s CKD Algorithm Panelon thenavify Algorithm Suite
Repatha is now the first and only PCSK9 inhibitor to demonstrate significant reduction of cardiovascular events as both primary and secondary prevention
Hyperion results presented at ERS 2025 and simultaneously published in the New England Journal of Medicine
Pegozafermin offers a distinct mechanism of action with potential for enhanced efficacy and tolerability and opportunities for combination development with incretins
EU approval makes Novo Nordisk’s oral semaglutide the first and only oral GLP-1 RA to reduce cardiovascular death, heart attack and stroke
Subscribe To Our Newsletter & Stay Updated
